And four other potential targets that could make sense for the beleaguered group.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.